Kineta Secures $1.8 Million Funding Boost from Wellcome Trust on Positive Phase 1a Clinical Study Results with LHF-535 Favorable overall

Kineta Secures NIAID Grant Worth Up to $5.8M to Evaluate LHF-535 in Arenaviruses Seattle, WA — (July 15, 2019) Kineta,

Kineta Invited to Participate at the Oppenheimer Summit for Emerging Life Sciences Conference Seattle, WA — (May 28, 2019) Kineta,

Kineta Enters Research Collaboration and License Agreement with Pfizer to Develop New Cancer Immunotherapies Kineta Immuno-Oncology to receive $15 million

Kineta Initiates First-in-Human Clinical Trial of LHF-535 a Novel Therapy for Lassa Fever Phase 1 study to assess the safety,

Collaboration to develop a first-in-class α9/α10 nicotinic acetylcholine receptor antagonist for the treatment of chronic pain Kineta to receive undisclosed

Kineta Immuno-oncology Unveils New Data Demonstrating Tumor Immunity in Multiple Tumor Models Small molecule RIG-I agonist induces innate immune responses,

Kineta Immuno-oncology to Present at Keystone Symposia on Molecular and Cellular Biology: Cancer Immunotherapy Combinations Conference New data on Kineta’s

Kineta Immuno-oncology Announces Presentation on Novel RIG-I Agonists at Immuno-Oncology Frontiers World Conference SEATTLE, WA, January 22, 2018 – Kineta